Cancel

From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the two PARP inhibitors, o...
Annenberg Center for Health Sciences at Eisenhower

Live Webinar: Diagnosis and Evidence-Based Management of T-Cell Lymphoma

Register today for this expert-led discussion presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health. This dynamic webinar will provide the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more! Don’t miss your chance to enhance y...
i3 Health

Video Viewpoint Strategy Session: Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma

Discover new and emerging treatment strategies for advanced classical Hogkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now! STATEMENT ...
i3 Health

Podcast: Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma

Discover new and emerging treatment strategies for advanced classical Hogkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now! STATEMENT ...
i3 Health

Metastatic Triple-Negative Breast Cancer: Applying Treatment Advances to Personalized Care

Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now! STATEMENT OF NEED With an estimated 284,200 new cases per year, breast cancer is the mo...
i3 Health

Video ViewPoint Strategy Session: Rethinking the Management of Differentiated and Anaplastic Thyroid Cancers

Gain expert insight and strategies for the management of anaplastic thyroid cancer including emerging data on immunotherapies, and treatment to manage adverse events. This activity is presented by leading experts, Jochen Lorch, MD, MSc, Director Thyroid Cancer Center, Dana-Farber Cancer Institute, and Carolyn Grande, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center. STATEMENT OF NEED Thyroid cancer is one of the most prevalent cancers in the United States. An estimated ...
i3 Health

Addressing Challenges in Diagnosis and Treatment of Low-Grade Upper Tract Urothelial Carcinoma

OVERVIEW Upper tract urothelial carcinoma (UTUC) has many similarities to bladder carcinoma, but also some important differences. Join Dr. Seth Lerner, as he contrasts these 2 diseases, as well as important differences between low-grade and high-grade UTUC. Dr. Lerner highlights important considerations in the instruments, imaging, and biopsy techniques for diagnosing low-grade UTUC. Surgical options are considered, with a focus on patient selection for endoscopic nephron-sparing surgery. The...
Annenberg Center for Health Sciences at Eisenhower

Video Viewpoint Strategy Session: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer 

Learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Start the activity now! STATEMENT OF NEED There are an estimated 13,800 new c...
i3 Health

Podcast: Update on Immunotherapeutic Strategies for Recurrent and Metastatic Cervical Cancer

In this episode of Oncology Data Advisor TM, learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Listen now! STATEMENT OF NEED Th...
i3 Health

Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity ...
i3 Health

Video Viewpoint Strategy Session: Optimizing Treatment and Functional Outcomes in Head and Neck Squamous Cell Carcinoma

Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Start the activity now. STATEMENT OF NEED H...
i3 Health

Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer

STATEMENT OF NEED Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use of routine screening is suboptimal, most patients are diagnosed at later stages (ACS, 2021)....
i3 Health

New Data and Emerging Management Strategies for Migraine Headache

STATEMENT OF NEED Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually every aspect of their lives, including personal relationships, reproductive choices, and productivity i...
i3 Health

Podcast: New Data and Emerging Management Strategies for Migraine Headache

STATEMENT OF NEED Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually every aspect of their lives, including personal relationships, reproductive choices, and productivity i...
i3 Health

Infusing Renewed Hope into Cancer-related Anemia with Intravenous Iron: AN EXPERT-LED EXPLORATION OF RECENT AND EMERGING TRIAL DATA AND CURRENT GUIDELINE RECOMMENDATIONS

Designed and developed to maximize digital audience reach and engagement, this Medical Moments webinar will review all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The activity will begin with a brief primer on iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An appraisal of the foundat...
CE Concepts

Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 1

STATEMENT OF NEED Multiple myeloma is a B-cell neoplasm that occurs primarily in older adults. The incidence is expected to rise in conjunction with the aging population. Because symptoms often do not appear until the malignancy is in advanced stages, early diagnosis is difficult, and the 5-year relative survival rate remains only 54% (ACS, 2021). Following diagnosis, management must be guided by cytogenic markers with prognostic significance and correct staging based upon these markers (NC...
i3 Health

Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2

STATEMENT OF NEED Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of...
i3 Health

Video Viewpoint Strategy Session: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer

Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now. STATEMENT OF NEED Squamous ce...
i3 Health

Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer

Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Start the activity now. STATEMENT OF NEED Squamous ce...
i3 Health

Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now. STATEMENT OF NEED Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Rana...
i3 Health

Improving Outcomes in Hodgkin Lymphoma

This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now. STATEMENT OF NEED Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed ...
i3 Health

Updates in Myelodysplastic Syndromes: Improving Patient Outcomes

This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now. STATEMENT OF NEED Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipot...
i3 Health

New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia

Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lmahiyerobo, MSN, APN, Advanced Practice Nurse at Hematology and Oncology Physicians of Englewood. Star...
i3 Health

Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer

This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. ...
i3 Health

Podcast: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer

This expert-led episode of Oncology Data Advisor TM, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non...
i3 Health

Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia

Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now. STATEMENT OF NEED Chemotherapy-induced neutropenia (CIN) is a potent...
i3 Health

Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia

Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing. Start the activity now. STATEMENT OF NEED Chemotherapy-induced neutropenia (CIN) is a potent...
i3 Health

Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer

Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine. Start the activity now! ...
i3 Health

Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer

This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of adv...
i3 Health

Innovations and New Practices in Internal Medicine 2022 -LIVE STREAMING

The State of the Art in Internal Medicine This Harvard Medical School CME program provides a comprehensive update of the most important changes impacting Internal Medicine and guidance to incorporate these advances into everyday clinical practice to improve patient outcomes. Practical, Fast-Paced, Case-Based Education This streaming educational experience is fast paced, relevant to the current healthcare environment, and draws upon real-life cases. The course is designed and led by Harv...
Harvard Medical School

Matching Treatment to Mutations: Clinical Pathways to Optimize RET+ Testing in NSCLC and Thyroid Cancer

Join the discussion! We bring the expert to you. LIVE. VIRTUAL. FLEXIBLE. Interactive discussion on optimization of RET+ testing in NSCLC and thyroid cancer, and the pathways for enhancing collaboration between pathologists and oncologists to improve patient care. Choose a date that works best with your schedule! Your questions answered on precision medicine! - What are the roles of biomarkers? - When should biomarker testing occur? - What do the test results mean? - How does the muta...
ACHL

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Host a complimentary Virtual Visiting Professorship Program (VPP): Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2. Easy-to-administer one-hour complimentary virtual independent medical education is available to your institution. We will coordinate a day and time that works for your intuition and bring the expert to you. ✔️ No cost to your organization (supported by an educational grant) ✔️ Approved fo...
ACHL

Hot Topics in Oncology – Focus on the Immune Checkpoint Inhibitors (ICIs)

The immune checkpoint inhibitors (ICIs) continue to break ground in a multitude of cancer types. With ever-evolving data and recommendations, oncology clinicians must keep pace with the latest ICI updates. This recorded CME-certified session tackles questions surrounding topics related to immune checkpoint inhibitors with discussion on: • Role of biomarkers with ICI selection and monitoring • Latest expanded ICI indications • Immune-related adverse events This session also featu...
ACHL

Exploring the Advent of Antibody-Drug Conjugates Across Multiple Tumor Types: Implications for Testing and Treatment Planning

Target Audience This educational program is directed toward the American Society of Clinical Oncology (ASCO) audience, including medical oncologists, pathologists, radiation oncologists, and surgical oncologists. Other attendees of the ASCO Annual Meeting who have an interest in the treatment of cancer, such as nurses, physician assistants, fellows, and residents, are also invited to participate. Program Overview This online, on-demand virtual symposium brings together renowned experts in...
Physicians’ Education Resource®, LLC

Top 10 Oncogenic Markers in Advanced NSCLC: What You Need to Know About Testing, Trials, and Novel Therapies

Target Audience This educational program is directed toward the American Society of Clinical Oncology (ASCO) audience, including medical oncologists, pathologists, and pulmonologists interested in the treatment of advanced NSCLC. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and those involved in the treatment of patients with advanced NSCLC, are also invited to participate. Program Overview In this online, on-demand virtual symposium...
Physicians’ Education Resource®, LLC

The Wolf in Sheep’s Clothing – Neuroendocrine Tumors (NETs)

Target Audience This activity is intended for physicians, PAs, pharmacists, nurse practitioners, registered nurses and other HCPs in primary care, GI, and oncology practice. Program Overview Neuroendocrine tumors are often misdiagnosed as irritable bowel syndrome and other diseases. They can also be found incidentally by colonoscopy, EGD, or CT scan. The program describes the next steps in primary care, GI, and oncology practice. Brief takeaways are included. Learning Objectives Upon ...
Postgraduate Institute for Medicine and P2P Syncro

Internal Medicine Comprehensive Review and Update 2022 - LIVE STREAMING

Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties This program, the 62nd Annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care. This program covers the breadth of Internal Medicine subspecialties, including: • Cardiovascular Medicine • Infectious...
Harvard Medical School

Safe and Effective Opioid Prescribing While Managing Acute and Chronic Pain

This course familiarizes physicians with current guidelines for opioid prescribing, including the management ofg acute and chronic back pain, how to assess the functional effects of pain in patients, and how to utilize a range of therapeutic options when managing patients with chronic pain. Outcome Objectives: As a result of completing this activity, the participant will be better able to: - Manage acute and chronic back pain. - Assess the functional effects of pain in patients. - A...
Virtual Lecture Hall (University of Arizona College of Medicine - Tucson)

Addressing Barriers to Improved Outcomes in African American Patients With Multiple Myeloma

Target Audience This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses. Program Overview Multiple myeloma is the second most common blood cancer in the United States, and its incidence in the African American population is twice that of Whites. This activity offers learners the opportunity to engage in clinical scenarios of multiple myeloma in African American patients presented as 3 case vignettes, each featuring an expert-led video clip. Through the...
Practicing Clinicians Exchange.

Exploring Current and Emerging Data Sets to Move Treatment of Higher-Risk MDS Forward: A Focus on Novel Targets and Treatment Approaches

Target Audience This educational program is directed toward the ASCO audience, including hematologists and medical oncologists interested in the treatment of HR-MDS. Other allied healthcare professionals, including pathologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with MDS are also invited to participate. Program Overview This online, on-demand virtual symposium brings together renowned ...
Physicians’ Education Resource®, LLC

Intensive Review of Internal Medicine - LIVE STREAMING

The Acclaimed Clinical Update and Board Review LIVE STREAMING and ON-DEMAND EDUCATION With more than 150 distance-learning lectures, case discussions, and board preparation sessions, this CME program is one of the most comprehensive reviews of internal medicine offered by the clinical faculty of Harvard Medical School. It offers accelerated learning: ► For clinicians seeking a practical and comprehensive review that ensures you are up to date across all major fields of internal med...
Harvard Medical School

Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care

The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indic...
Postgraduate Institute for Medicine

Maximizing the Benefits of Targeted Cancer Treatment with PI3K Inhibitors

Target Audience This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses. Program Overview Significant advances in targeted and immunotherapies in recent years have revolutionized the treatment of cancer. Among the new therapeutic options are the phosphatidylinositol-3-kinase (PI3K) inhibitors, which have demonstrated efficacy in both hematologic malignancies and solid tumors, albeit at the price of a high risk of serious adverse effects. To date, the U...
Practicing Clinicians Exchange

Strategies for PD-L1 Testing and Targeted Therapy With Immune Checkpoint Inhibitors for NSCLC

Target Audience Oncology physicians, nurse practitioners, physician assistants; pulmonary physicians, nurse practitioners, physician assistants; pathologists and pharmacists. Program Overview Despite advances in the treatment of non-small cell lung cancer (NSCLC), overall 5-year survival has not significantly improved in recent years. Newly approved and emerging immune checkpoint inhibitor (ICI) therapies offer improvements in survival over chemotherapy alone, but toxicities and immune-re...
Rutgers Biomedical and Health Sciences and Spire Learning

Nuclear Medicine and Molecular Imaging Inside Out

The Mid East Chapter of the Society of Nuclear Medicine and Molecular Imaging presents its 49th Annual Meeting. Nuclear Medicine and Molecular Imaging Inside Out features fifteen faculty members discussing a wide range of topics demonstrating the specialty’s impact on imaging, cardiology, oncology, neurology and much more. This activity will allow physicians and technologists to stay current with this constantly developing medical discipline. Worth up to 15.25 AMA PRA Category I Credits™,...
Meetings By Mail®

Oncology Innovations: Novel Approaches to Immunotherapy in mESCC

Target Audience This activity is designed to meet the educational needs of medical oncologists, gastroenterologists, and other HCPs who treat patients with esophageal carcinoma. Program Overview This activity will cover the advances in the therapeutic paradigm for patients with esophageal carcinoma in a digital, interactive infographic format. Learning Objectives Upon completion of this activity, participants should be better able to: Develop treatment strategies for patients wit...
Postgraduate Institute for Medicine and DKBmed, LLC

RCC Treatment Strategies in a Poor-Risk Patient

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and dis...
ACHL

Promoting Recognition, Diagnosis, and Treatment of Cold Agglutinin Disease

TARGET AUDIENCE: This activity was developed for adult hematologists, hematologist-oncologists, hematology-oncology nurse practitioners, emergency physicians, primary care physicians, and other clinicians involved in the management of patients with cold agglutinin disease. PROGRAM OVERVIEW: Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understandi...
Annenberg Center for Health Sciences at Eisenhower

Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multiple Myeloma

Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now! STATEMENT OF NEED Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramed...
i3 Health

RCC Treatment Strategies in a Favorable-Risk Patient

Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize o...
ACHL

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map